Cited by 3,114T-cell and B-cell ImmunologyCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.

Molecular mechanisms of T cell co-stimulation and co-inhibition

Open access

Chen, Lieping, Flies, Dallas B.·2013·Nature Reviews Immunology

Open this paper in CoChat — free account

Abstract

Co-stimulatory and co-inhibitory receptors have a pivotal role in T cell biology, as they determine the functional outcome of T cell receptor (TCR) signalling. The classic definition of T cell co-stimulation continues to evolve through the identification of new co-stimulatory and co-inhibitory receptors, the biochemical characterization of their downstream signalling events and the delineation of their immunological functions. Notably, it has been recently appreciated that co-stimulatory and co-inhibitory receptors display great diversity in expression, structure and function, and that their functions are largely context dependent. Here, we focus on some of these emerging concepts and review the mechanisms through which T cell activation, differentiation and function is controlled by co-stimulatory and co-inhibitory receptors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nri3405

Cites

135 of 135 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citation
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
T cell exhaustion
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
The B7 family revisited
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,072
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860

Flagged first, then by citations

Show all 135 references

Research works printed but not linked: 1

Lafferty, K. J. & Cunningham, A. J. A. New analysis of allogeneic interactions. J. Immunol. 112, 436–437 (1975). Lafferty and Cunningham extended the Bretscher and Cohn two-signal model to suggest that T cells require two signals for activation.

Sorted by citations

Items 401–500 of 1,003

Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC
Champiat, S., Ileana, E. E., Giaccone, G., Besse, B., Mountzios, G., Eggermont, A. M. M., & Soria, J. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000074 · Cited by 96
T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling
Josefsson, S. E., Huse, K., Kolstad, A., Beiske, K., Pende, D., Steen, C. B., Inderberg, E. M., Lingjærde, O. C., Østenstad, B., Smeland, E. B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2337 · Cited by 98
An immunoregulatory and tissue-residency program modulated by c-MAF in human TH17 cells
Aschenbrenner, D., Foglierini, M., Jarrossay, D., Hu, D., Weiner, H. L., Kuchroo, V. K., Lanzavecchia, A., Notarbartolo, S., & Sallusto, F. (2018) · Nature Immunology · doi:10.1038/s41590-018-0200-5 · Cited by 101
Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy
Rath, J. A., & Arber, C. (2020) · Cells · doi:10.3390/cells9061485 · Cited by 104
PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity
Sugiura, D., Okazaki, I., Maeda, T. K., Maruhashi, T., Shimizu, K., Arakaki, R., Takemoto, T., Ishimaru, N., & Okazaki, T. (2022) · Nature Immunology · doi:10.1038/s41590-021-01125-7 · Cited by 102
Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy
Adachi, K., & Tamada, K. (2015) · Cancer Science · doi:10.1111/cas.12695 · Cited by 99
Foxp3+ Tregs are recruited to the retina to repair pathological angiogenesis
Deliyanti, D., Talia, D. M., Zhu, T., Maxwell, M. J., Agrotis, A., Jerome, J. R., Hargreaves, E. M., Gerondakis, S., Hibbs, M. L., Mackay, F., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00751-w · Cited by 95
The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment
Bolandi, N., Derakhshani, A., Hemmat, N., Baghbanzadeh, A., Asadzadeh, Z., Nour, M. A., Brunetti, O., Bernardini, R., Silvestris, N., & Baradaran, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910719 · Cited by 97
CD8 + T cell exhaustion in anti‐tumour immunity: The new insights for cancer immunotherapy
Huang, Y., Jia, A., Wang, Y., & Liu, G. (2022) · Immunology · doi:10.1111/imm.13588 · Cited by 96
“In this process, costimulatory molecules (such as CD28) are also involved [1].”
Background
Regulation of CD8+ T memory and exhaustion by the mTOR signals
Chen, Y., Xu, Z., Sun, H., Ouyang, X., Han, Y., Yu, H., Wu, N., Xie, Y., & Su, B. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01064-3 · Cited by 101
“In general, TCR stimulation induces signaling via the ERK/MAPK pathway and calcium influx, while CD28 signaling triggers the activation of the PI3K-Akt-mTOR axis [128, 129].”
Background
Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy
Bamias, G., Delladetsima, I. K., Perdiki, Μ., Siakavellas, S. I., Goukos, D., Papatheodoridis, G., Daikos, G. L., & Gogas, H. J. (2017) · Cancer Investigation · doi:10.1080/07357907.2017.1324032 · Cited by 96
Negative co-stimulation constrains T cell differentiation by imposing boundaries on possible cell states
Wei, S. C., Sharma, R., Anang, N.-A. A. S., Levine, J. H., Zhao, Y., Mancuso, J. J., Setty, M., Sharma, P., Wang, J., Pe’er, D., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.004 · Cited by 97
Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation
Teijeira, Á., Labiano, S., Garasa, S., Etxeberría, I., Santamaría, E., Rouzaut, A., Enamorado, M., Azpilikueta, A., Inogés, S., Bolaños, E., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0767 · Cited by 99
Immunobiology of T Cells in Sjögren’s Syndrome
Yao, Y., Ma, J.-F., Chang, C. C.-C., Xu, T., Gao, C., Gershwin, M. E., & Lian, Z. (2020) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08793-7 · Cited by 99
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
Yang, X., Ma, L., Zhang, X., Huang, L., & Wei, J. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00263-4 · Cited by 103
Nicotinamide metabolism face-off between macrophages and fibroblasts manipulates the microenvironment in gastric cancer
Jiang, Y., Wang, Y., Chen, G., Sun, F., Wu, Q., Huang, Q., Zeng, D., Qiu, W., Wang, J., Yao, Z., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.013 · Cited by 101
Immune-checkpoint protein VISTA critically regulates the IL-23/IL-17 inflammatory axis
Li, N., Xu, W., Yuan, Y., Ayithan, N., Imai, Y., Wu, X., Miller, H. E., Olson, M., Feng, Y., Huang, Y. H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01411-1 · Cited by 99
The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer
Alemohammad, H., Najafzadeh, B., Asadzadeh, Z., Baghbanzadeh, A., Ghorbaninezhad, F., Najafzadeh, A., Safarpour, H., Bernardini, R., Brunetti, O., Sonnessa, M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112516 · Cited by 92
Regulation of atherosclerotic plaque inflammation
Bäck, M., Weber, C., & Lutgens, E. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12367 · Cited by 98
New Strategies in Bladder Cancer: A Second Coming for Immunotherapy
Ghasemzadeh, A., Bivalacqua, T. J., Hahn, N. M., & Drake, C. G. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1135 · Cited by 93
Ubc13: the Lys63 ubiquitin chain building machine
Hodge, C. D., Spyracopoulos, L., & Glover, J. N. M. (2016) · Oncotarget · doi:10.18632/oncotarget.10948 · Cited by 99
Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity
Watanabe, R., Shirai, T., Namkoong, H., Zhang, H., Berry, G. J., Wallis, B. B., Schaefgen, B., Harrison, D. G., Tremmel, J. A., Giacomini, J. C., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92167 · Cited by 97
Engineering challenges for brain tumor immunotherapy
Lyon, J. G., Mokarram, N., Saxena, T. K., Carroll, S. L., & Bellamkonda, R. V. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.006 · Cited by 102
Clinical Implications of Aberrant PD-1 and CTLA4 Expression for Cancer Immunity and Prognosis: A Pan-Cancer Study
Liu, J., Kong, X., Huang, T., Wang, R., Li, W., & Chen, Q. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02048 · Cited by 93
Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy
Hao, Z., Li, R., Wang, Y., Li, S., Hong, Z., & Han, Z. (2021) · Biomarker Research · doi:10.1186/s40364-021-00333-5 · Cited by 101
Unlocking the power of NOX2: A comprehensive review on its role in immune regulation
Bode, K., Hauri-Hohl, M. M., Jaquet, V., & Weyd, H. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102795 · Cited by 103
Impaired function of dendritic cells within the tumor microenvironment
Xiao, Z., Wang, R., Wang, X., Yang, H., Dong, J.-M., He, X., Yang, Y., Guo, J., Cui, J., & Zhou, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1213629 · Cited by 105
“with CTLA-4 having a greater affinity and avidity than CD28 (61).”
Background
The role of lymphocytes in the development and treatment of alopecia areata
Guo, H., Cheng, Y., Shapiro, J., & McElwee, K. J. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.1085306 · Cited by 94
Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines
Lohmueller, J. J., & Finn, O. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.008 · Cited by 96
Cardiac Complications in Immune Checkpoint Inhibition Therapy
Tajiri, K., & Ieda, M. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00003 · Cited by 95
In vitro reconstitution of T cell receptor-mediated segregation of the CD45 phosphatase
Carbone, C. B., Kern, N., Fernandes, R. A., Hui, E., Su, X., García, K. C., & Vale, R. D. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710358114 · Cited by 91
EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients
Zhu, G., Pei, L., Li, Y., & Gou, X. (2020) · Aging · doi:10.18632/aging.102728 · Cited by 93
Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment
Onuma, A. E., Zhang, H., Huang, H., Williams, T. M., Noonan, A. M., & Tsung, A. (2020) · Gene Expression · doi:10.3727/105221620x15880179864121 · Cited by 95
Targeting PD-L1 in non-small cell lung cancer using CAR T cells
Liu, M., Wang, X., Li, W., Yu, X., Flores-Villanueva, P. O., Xu-Monette, Z. Y., Li, L., Zhang, M., Young, K. H., Ma, X., et al. (2020) · Oncogenesis · doi:10.1038/s41389-020-00257-z · Cited by 95
Mechanistic Rationales Guiding Combination Hepatocellular Carcinoma Therapies Involving Immune Checkpoint Inhibitors
Cheu, J. W., & Wong, C. C. (2021) · Hepatology · doi:10.1002/hep.31840 · Cited by 91
Transdermal immunomodulation: Principles, advances and perspectives
Zhao, Z., Ukidve, A., Dasgupta, A., & Mitragotri, S. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.03.010 · Cited by 92
Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor–Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors
Heinhuis, K. M., Carlino, M. S., Joerger, M., Nicola, M. D., Meniawy, T. M., Rottey, S., Moreno, V., Gazzah, A., Delord, J., Paz-Ares, L. G., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3848 · Cited by 90
Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells
Romero, Y., Wise, R., & Żółkiewska, A. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02437-2 · Cited by 94
Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
Chocarro, L., Zuazo, M., Arasanz, H., Bocanegra, A., Hernandez, C., Fernández, G., García-Granda, M. J., Blanco, E., Vera, R., Kochan, G. T., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00441 · Cited by 94
Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
Castelletti, L., Yeo, D., van Zandwijk, N., & Rasko, J. E. J. (2021) · Biomarker Research · doi:10.1186/s40364-021-00264-1 · Cited by 95
Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade
Tian, T., & Li, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.731175 · Cited by 100
Tim-3 Directly Enhances CD8 T Cell Responses to Acute Listeria monocytogenes Infection
Gorman, J. V., Starbeck-Miller, G. R., Pham, N., Traver, G. L., Rothman, P. B., Harty, J. T., & Colgan, J. D. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302290 · Cited by 91
Control of Immunoregulatory Molecules by miRNAs in T Cell Activation
Rodríguez‐Galán, A., Fernández‐Messina, L., & Sánchez‐Madrid, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02148 · Cited by 88
CD38: T Cell Immuno-Metabolic Modulator
Kar, A., Mehrotra, S., & Chatterjee, S. (2020) · Cells · doi:10.3390/cells9071716 · Cited by 94
Targeting Cbl-b in cancer immunotherapy
Augustin, R. C., Bao, R., & Luke, J. J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006007 · Cited by 92
Notch Signaling Regulates Antigen Sensitivity of Naive CD4+ T Cells by Tuning Co-stimulation
Laky, K., Evans, S., Pérez‐Díez, A., & Fowlkes, B. J. (2015) · Immunity · doi:10.1016/j.immuni.2014.12.027 · Cited by 93
Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids
Meng, Q., Xie, S., Gray, G. K., Dezfulian, M. H., Gandarilla, O., Li, W., Huang, L., Akshinthala, D., Ferrer, E., Conahan, C., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003213 · Cited by 90
Surfing the Protein-Protein Interaction Surface Using Docking Methods: Application to the Design of PPI Inhibitors
Sable, R. V., & Jois, S. D. S. (2015) · Molecules · doi:10.3390/molecules200611569 · Cited by 93
Delivery Strategies for Immune Checkpoint Blockade
Chen, Q., Wang, C., Chen, G., Hu, Q., & Gu, Z. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800424 · Cited by 90
TGF-β1 promotes colorectal cancer immune escape by elevating B7-H3 and B7-H4viathe miR-155/miR-143 axis
Zhou, X., Mao, Y., Zhu, J., Meng, F., Chen, Q., Tao, L., Li, R., Fu, F., Liu, C., Yuanjia, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11950 · Cited by 92
Beyond Cell Death: New Functions for TNF Family Cytokines in Autoimmunity and Tumor Immunotherapy
Yi, F., Frazzette, N., Cruz, A. C., Klebanoff, C. A., & Siegel, R. M. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.05.004 · Cited by 89
Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas
Kim, S., Hyeon, J., Cho, I., Ko, Y. H., & Kim, W. S. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2018.191 · Cited by 89
Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity
Álvarez‐Sierra, D., Marín, A., Ruiz-Blázquez, P., de Jesús‐Gil, C., Iglesias, C., González, Ó., Casteràs, A., Ferrer, R., Nuciforo, P. G., Colobrán, R., et al. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.05.013 · Cited by 89
Multiregion single‐cell sequencing reveals the transcriptional landscape of the immune microenvironment of colorectal cancer
Wang, W., Zhong, Y., Zhuang, Z., Xie, J., Lu, Y., Huang, C., Sun, Y., Wu, L. L., Yin, J., Yu, H., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.253 · Cited by 91
Crosstalk between Macrophages, T Cells, and Iron Metabolism in Tumor Microenvironment
Shen, L., Zhou, Y., He, H., Chen, W., Lenahan, C., Li, X., Deng, Y., Shao, A., & Huang, J. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/8865791 · Cited by 92
T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword
Simons, K. H., de Jong, A., Jukema, J. W., de Vries, M. R., Arens, R., & Quax, P. H. A. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0164-7 · Cited by 89
Engineering human stem cell-derived islets to evade immune rejection and promote localized immune tolerance
Gerace, D., Zhou, Q., Kenty, J. H.-R., Veres, A., Sintov, E., Wang, X., Boulanger, K. R., Li, H., & Melton, D. A. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100879 · Cited by 88
(Dis)respect and black mortality.
Kennedy, B. P., Kawachi, I. I., Lochner, K. A., Jones, C., & Prothrow‐Stith, D. (1997) · PubMed · Cited by 85
HTLV-1 bZIP Factor Impairs Anti-viral Immunity by Inducing Co-inhibitory Molecule, T Cell Immunoglobulin and ITIM Domain (TIGIT)
Yasuma-Mitobe, K., Yasunaga, J., Takemoto, K., Sugata, K., Mitobe, Y., Takenouchi, N., Nakagawa, M., Suzuki, Y., & Matsuoka, M. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005372 · Cited by 94
T Cells and Gene Regulation: The Switching On and Turning Up of Genes after T Cell Receptor Stimulation in CD8 T Cells
Conley, J. M., Gallagher, M. P., & Berg, L. J. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00076 · Cited by 88
Microfluidic single-cell technology in immunology and antibody screening
Seah, S., Hu, H., & Merten, C. A. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.09.004 · Cited by 87
Chemoradiation-Induced Alteration of Programmed Death-Ligand 1 and CD8+ Tumor-Infiltrating Lymphocytes Identified Patients With Poor Prognosis in Rectal Cancer: A Matched Comparison Analysis
Lim, Y. J., Koh, J., Kim, S., Jeon, S. R., Chie, E. K., Kim, K., Kang, G. H., Han, S., Kim, T., Jeong, S., et al. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.07.004 · Cited by 87
Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells
Rossi, J., Céballos, P., & Lu, Z. (2019) · 癌症：英文版 · doi:10.1186/s40880-019-0379-3 · Cited by 89
Cellular immunotherapies for cancer
Hayes, C. (2020) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-020-02264-w · Cited by 91
MicroRNAs and Their Influence on the ZEB Family: Mechanistic Aspects and Therapeutic Applications in Cancer Therapy
Ashrafizadeh, M., Ang, H. L., Moghadam, E. R., Mohammadi, S., Zarrin, V., Hushmandi, K., Samarghandian, S., Zarrabi, A., Najafi, M., Mohammadinejad, R., et al. (2020) · Biomolecules · doi:10.3390/biom10071040 · Cited by 87
Recent advances in immunotherapy, immunoadjuvant, and nanomaterial-based combination immunotherapy
Zhou, B., Liu, J., Lin, M., Zhu, J., & Chen, W. R. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214009 · Cited by 86
Optimization of metabolism to improve efficacy during CAR-T cell manufacturing
Zhang, M., Jin, X. K., Sun, R., Xiong, X., Wang, J., Xie, D., & Zhao, M. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03165-x · Cited by 90
From DNA Damage to Nucleic Acid Sensing: A Strategy to Enhance Radiation Therapy
Deng, L., Liang, H. L., Fu, S., Weichselbaum, R. R., & Fu, Y. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3110 · Cited by 87
Genetic alterations in adult T‐cell leukemia/lymphoma
Kogure, Y., & Kataoka, K. (2017) · Cancer Science · doi:10.1111/cas.13303 · Cited by 91
Select sequencing of clonally expanded CD8 + T cells reveals limits to clonal expansion
Huang, H., Sikora, M. J., Islam, S., Chowdhury, R. R., Chien, Y., Scriba, T. J., Davis, M. M., & Steinmetz, L. M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902649116 · Cited by 86
Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood
Smith, C. J., Ross, N., Kamal, A., Kim, K. Y., Kropf, E., Deschatelets, P., Francois, C., Quinn, W. J., Singh, I., Majowicz, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.999021 · Cited by 86
A Platform for Extracellular Interactome Discovery Identifies Novel Functional Binding Partners for the Immune Receptors B7-H3/CD276 and PVR/CD155
Husain, B., Ramani, S. R., Chiang, E. Y., Lehoux, I. E., Paduchuri, S., Arena, T. A., Patel, A., Wilson, B., Chan, P., Franke, Y., et al. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.tir119.001433 · Cited by 86
Tumor regulation of the tissue environment in the liver
Eggert, T., & Greten, T. F. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.005 · Cited by 86
Tertiary Lymphoid Structure-B Cells Narrow Regulatory T Cells Impact in Lung Cancer Patients
Germain, C., Devi-Marulkar, P., Knockaert, S., Biton, J., Kaplon, H., Letaïef, L., Goc, J., Seguin‐Givelet, A., Gossot, D., Girard, N., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.626776 · Cited by 89
Characteristics and anatomic location of PD-1 + TCF1 + stem-like CD8 T cells in chronic viral infection and cancer
Im, S. J., Obeng, R. C., Nasti, T. H., McManus, D. T., Kamphorst, A. O., Gunisetty, S., Prokhnevska, N., Carlisle, J. W., Yu, K., Sica, G., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221985120 · Cited by 88
“XCR1 is the sole known receptor of XCL1 and is selectively expressed on the surface of CD8 α + lymphoid DCs, also referred to as type 1 conven tional dendritic cells (cDC1) (52).”
Background
Immune checkpoint modulation: Rational design of combination strategies
Zamarin, D., & Postow, M. A. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.01.003 · Cited by 85
Rationale for anti-CD137 cancer immunotherapy
Makkouk, A., Chester, C., & Kohrt, H. E. K. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.09.026 · Cited by 84
T Cell–Macrophage Interactions and Granuloma Formation in Vasculitis
Hilhorst, M. L., Shirai, T., Berry, G. J., Goronzy, J. J., & Weyand, C. M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00432 · Cited by 84
The immunoinhibitory PD-1/PD-L1 pathway in inflammatory blood vessel disease
Weyand, C. M., Berry, G. J., & Goronzy, J. J. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.3ma0717-283 · Cited by 85
Immunotherapy in pancreatic cancer treatment: a new frontier
Thind, K., Padrnos, L. J., Ramanathan, R. K., & Borad, M. J. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16667909 · Cited by 83
Surface protein imputation from single cell transcriptomes by deep neural networks
Zhou, Z., Ye, C., Wang, J., & Zhang, N. R. (2020) · Nature Communications · doi:10.1038/s41467-020-14391-0 · Cited by 86
Immune Checkpoint Inhibitors in Cancer Therapy—How to Overcome Drug Resistance?
Lao, Y., Shen, D., Zhang, W., He, R., & Jiang, M. (2022) · Cancers · doi:10.3390/cancers14153575 · Cited by 87
“CTLA-4 also mediates the transendocytosis of APCs on B7-1 and B7-2, preventing their binding to CD28 and reducing the availability of CD28 [30,31].”
Background
Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer
Weeden, C. E., Gayevskiy, V., Marceaux, C., Batey, D., Tan, T., Yokote, K., Ribera, N. T., Clatch, A., Christo, S. N., Teh, C. E., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.03.019 · Cited by 83
TLR4 Activation Enhances the PD-L1–Mediated Tolerogenic Capacity of Colonic CD90+ Stromal Cells
Beswick, E. J., Johnson, J. R., Saada, J. I., Humen, M. A., House, J., Dann, S. M., Qiu, S., Brasier, A. R., Powell, D. W., Reyes, V. E., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1203441 · Cited by 82
Untitled work
(2015) · Iranian Journal of Kidney Diseases · Cited by 82
Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells
Kozela, E., Juknat, A., Gao, F., Kaushansky, N., Coppola, G., & Vogel, Z. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0603-x · Cited by 84
Encapsulation of Hydrophilic and Hydrophobic Peptides into Hollow Mesoporous Silica Nanoparticles for Enhancement of Antitumor Immune Response
Xie, J., Yang, C., Liu, Q., Li, J., Liang, R., Shen, C., Zhang, Y., Wang, K., Liu, L., Shezad, K., et al. (2017) · Small · doi:10.1002/smll.201701741 · Cited by 82
Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab
Zhang, F., Qi, X., Wang, X., Wei, D., Wu, J., Feng, L., Cai, H., Wang, Y., Zeng, N., Xu, T., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21652 · Cited by 79
Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
Kiaie, S. H., Salehi‐Shadkami, H., Sanaei, M., Azizi, M., Barough, M. S., Nasr, M. S., & Sheibani, M. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02083-y · Cited by 83
Tr1-Like T Cells – An Enigmatic Regulatory T Cell Lineage
White, A. M., & Wraith, D. C. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00355 · Cited by 81
Aiming for cure in HBV and HDV infection
Petersen, J., Thompson, A. J. V., & Levrero, M. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.043 · Cited by 80
Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups
Netanely, D., Avraham, A., Ben‐Baruch, A., Evron, E., & Ron Shamir, A. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0724-2 · Cited by 77
Toll-Like Receptor 7 Activation Enhances CD8+ T Cell Effector Functions by Promoting Cellular Glycolysis
Li, Q., Yan, Y., Liu, J., Huang, X., Zhang, X., Kirschning, C. J., Xu, H. C., Lang, P. A., Dittmer, U., Zhang, E., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02191 · Cited by 81
Why do intestinal epithelial cells express MHC class II?
Heuberger, C., Pott, J., & Maloy, K. J. (2020) · Immunology · doi:10.1111/imm.13270 · Cited by 79
CD155/TIGIT, a novel immune checkpoint in human cancers (Review)
Liu, L., You, X., Han, S., Sun, Y., Zhang, J., & Zhang, Y. (2021) · Oncology Reports · doi:10.3892/or.2021.7943 · Cited by 80
The state of the art of bispecific antibodies for treating human malignancies
Wang, S., Chen, K., Lei, Q., Ma, P., Yuan, A. Q., Zhao, Y. J., Jiang, Y., Hong, F., Xing, S., Fang, Y., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114291 · Cited by 85
Peripheral human CD4+CD8+ T lymphocytes exhibit a memory phenotype and enhanced responses to IL-2, IL-7 and IL-15
Clénet, M., Gagnon, F., Moratalla, A. C., Viel, É. C., & Arbour, N. (2017) · Scientific Reports · doi:10.1038/s41598-017-11926-2 · Cited by 82
Immunomodulatory Bonds of the Partnership between Dendritic Cells and T Cells
Bourque, J., & Hawiger, D. (2018) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2018026790 · Cited by 79
Recharacterizing Tumor-Infiltrating Lymphocytes by Single-Cell RNA Sequencing
Zhang, L., & Zhang, Z. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0658 · Cited by 77
Immunology of Adenoviral Vectors in Cancer Therapy
Shaw, A. R., & Suzuki, M. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.11.001 · Cited by 81

Authors: Chen, L., & Flies, D. B.
Affiliations: Yale Cancer Center (US)
University of New Mexico (US)
Corresponding author: Chen, Lieping
ORCID: Chen, Lieping
Flies, Dallas B.
Venue: Nature Reviews Immunology
Publisher: Springer Science and Business Media LLC
Published: 2013-03-08
Volume: 13
Issue: 4
Pages: 227-242
ISSN: 1474-1733 (ISSN-L)
1474-1741
DOI: 10.1038/nri3405
PMC: PMC3786574
OpenAlex: W2130473166
Cited by: 3,114
References: 135
Citations by year: 2026: 148 · 2025: 258 · 2024: 259 · 2023: 276 · 2022: 305 · 2021: 312 · 2020: 310 · 2019: 250 · 2018: 275 · 2017: 238 · 2016: 195 · 2015: 148 · 2014: 101 · 2013: 35
FWCI: 13.52
Type: journal article
Language: en
Update notices: erratum (2013-06-05)
Open access: green
europepmc.org
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature reviews. Immunology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Melanoma Research Alliance
National Cancer Institute (CA 97085, CA 16359, CA121974, CA86721, R01CA097085, CA142779, R01CA085721, R01CA142779, P50CA121974, P30CA016359)
National Institute of Allergy and Infectious Diseases (T32AI089704, R01AI072592, AI72592, T32AI007247)
Topics: Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: T cell costimulation, T cell co-inhibition, costimulatory receptors, co-inhibitory receptors, T cell receptor signaling, T cell activation, T cell differentiation, immune checkpoint molecules
MeSH terms: Humans, Lymphocyte Activation, Receptors, Antigen, T-Cell, T-Lymphocytes, Signal Transduction, CD28 Antigens, B7-1 Antigen, Models, Immunological, B7-2 Antigen, Receptors, Tumor Necrosis Factor, Member 14

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Molecular mechanisms of T cell co-stimulation and co-inhibition

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks